A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Inclusion Criteria

• •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
• •Have an estimated life expectancy of greater than or equal to (≥)12 weeks
• •Have adequate organ function
• •Have received 1-4 prior systemic therapies for locally advanced or metastatic disease
• •Agree to use medically approved contraceptives during the study and for 3 months following the last study treatment
• •All females must have a negative serum pregnancy test result, and females of child-bearing potential must have a negative urine pregnancy test result, prior to the first study treatment
• •Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• •Must be, in the judgment of the investigator, an appropriate candidate for experimental therapy, and no standard therapy would confer clinical benefit
• •For Part A
• •Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain tumor) that is advanced or metastatic
• •For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450 (CYP2D6) poor metabolizer phenotype
• •For Part B
• •Have advanced or metastatic colorectal cancer, triple negative breast cancer (per American Society of Clinical Oncology-College of American Pathology guidelines), epithelial ovarian cancer, endometrial, soft tissue sarcoma, pancreatic cancer
• •* For TNBC:
• •* Recurrent/refractory Triple Negative Breast Cancer (TNBC) defined as any beast cancer that expresses \<1% estrogen receptor (ER) and \<1% progesterone receptor (PR) and is Her2 negative
• •* For Colorectal (CRC):
• •* Must have histologically confirmed advanced or metastatic colorectal cancer
• •* For Ovarian Cancer:
• •* Must have histologically confirmed advanced or metastatic epithelial ovarian cancer
• •* Must be eligible to receive Gemzar (GEM) and not refractory to GEM/carboplatin
• •* Must have the ability to tolerate GEM
• •* May have received GEM as previous therapy
• •* For Endometrial cancer:
• •* Must have histologically confirmed endometrial cancer that is metastatic or locally advanced
• •* Must have failed at least 1 prior chemotherapy
• •* For STS:
• •* Must have histologically confirmed STS that is metastatic or locally advanced
• •* Patients with gastrointestinal stromal tumors (GIST) must have failed a KIT inhibitor
• •* Must have failed at least 1 prior chemotherapy
• •* For Pancreatic Cancer:
• •* Must have histologically confirmed pancreatic cancer that is metastatic or locally advanced
• •* Must have failed at least 1 prior chemotherapy regimen
• •* For Part C
• •* Participants with high grade serous ovarian cancer (HGSOC) will be screened for specific genetic signatures